)
)
)
Nasus Pharma vision is to offer better protection to patients during acute, severe and life-threatening medical conditions by an effective, user-friendly, safe and immediately active powder-based Intranasal specialized products. Nasus pharma brings the new frontier in Intranasal drug delivery. Late-Stage Specialty Pharma company, offers Powder-Based Intranasal (PBI) specialized product portfolio, to address acute medical conditions and public health threats. Nasax® – proprietary powder formulation for intranasal delivery comprised of uniform spherical API and a carrier approved for inhalation. Technology aims for a rapid and precise delivery of the drug to the bloodstream and brain. Stability data demonstrated potential for longer shelf life.
Year Founded
2019
Expected time of next catalyst update
Next major inflection point anticipated in January 2028.
City
Tel Aviv
Country
Israel
Company CEO or top company official
Dan Teleman
Development Phase of Primary Product
Phase II
Exchange
NYSE: American
Lead Product in Development
IP-001 is a cationic polymer designed to utilize antigens/tumor debris liberated from approved, traditional interventional oncology procedures (such as tumor ablation) or other methodologies of tumor destruction like radiation therapy, transforming such routine tumor-destruction techniques into a systemic immunotherapy.
Therapeutic Area
Multiple Therapeutics
Ticker
NSRX
Website
https://www.nasuspharma.com/
){kind=logo}
)
)
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}
){kind=logo}
